Form 4: Enliven Therapeutics COO Anish Patel Reports Sale of Common Stock

Anish Patel, COO of Enliven Therapeutics, reported the sale of 716 shares of common stock at a weighted average price of $30.0035.

Summary

• Anish Patel, the Chief Operating Officer of Enliven Therapeutics, Inc. [ELVN], reported a transaction involving the sale of common stock on October 18, 2024.
• The transaction involved the sale of 716 shares at a weighted average price of $30.0035.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 29, 2023.
• Following the reported transaction, Patel indirectly owns 343,311 shares through The Patel / Dong Family Trust Dated August 24 2017, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider stock sale. It doesn't inherently convey positive or negative sentiment, as the sale was pre-planned under a 10b5-1 trading plan.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company executives. It is common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, but the existence of a pre-arranged trading plan mitigates concerns about insider information being used for personal gain.

Key Dates